Eli Lilly and Company (LLY)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $1.29T
Last updated: Nov 17, 2026 at 11:06 AM ET
Eli Lilly and Company (LLY) Financials: Revenue, Profit and Cash Flow
Eli Lilly and Company reported revenue of $65.18B for the fiscal year ended Dec 31, 2025, up 44.7% from the year before. That year, net income was $20.64B with a net margin of 31.7%, operating cash flow was $16.81B and free cash flow was $8.97B. The quarter ended Sep 30, 2026 had revenue of $24.40B and net income of $6.45B.
Revenue and Margins
The operating margin was 40.4% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $21.22B, a compound annual rate of 13.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $65.18B | +44.7% | 83.0% | 40.4% | 31.7% |
| Dec 2024 | $45.04B | +32.0% | 81.3% | 28.6% | 23.5% |
| Dec 2023 | $34.12B | +19.6% | 79.2% | 18.9% | 15.4% |
| Dec 2022 | $28.54B | +0.8% | 76.8% | 25.0% | 21.9% |
| Dec 2021 | $28.32B | +15.4% | 74.2% | 22.4% | 19.7% |
| Dec 2020 | $24.54B | +9.9% | 77.7% | 24.7% | 25.2% |
| Dec 2019 | $22.32B | +3.8% | 78.8% | 22.3% | 37.3% |
| Dec 2018 | $21.49B | +7.6% | 78.2% | 16.4% | 15.0% |
| Dec 2017 | $19.97B | -5.9% | 77.7% | 10.0% | -1.0% |
| Dec 2016 | $21.22B | N/A | 73.1% | 15.4% | 12.9% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 94.9% from the year before. In the quarter ended Sep 2026, net income rose 15.6% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B | $21.49B | $19.97B | $21.22B |
| Cost of revenue | $11.05B | $8.42B | $7.08B | $6.63B | $7.31B | $5.48B | $4.72B | $4.68B | $4.45B | $5.71B |
| Gross profit | $54.13B | $36.63B | $27.04B | $21.91B | $21.01B | $19.06B | $17.60B | $16.81B | $15.53B | $15.51B |
| Research and development | $16.25B | $14.27B | $13.11B | $8.10B | $7.90B | $6.75B | $5.83B | $7.04B | $6.21B | $5.34B |
| Operating income | $26.30B | $12.90B | $6.46B | $7.13B | $6.36B | $6.06B | $4.97B | $3.53B | $2.00B | $3.26B |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | -$204.10M | $2.74B |
| EBITDA | $27.73B | $14.45B | $8.08B | $8.33B | $7.70B | $8.55B | $6.50B | $5.29B | $3.87B | $4.87B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.40B | $22.97B | $19.80B | $19.29B | $17.60B | $15.56B | $12.73B | $13.53B | $11.44B | $11.30B | $8.77B | $9.35B |
| Gross profit | $20.46B | $19.71B | $16.22B | $15.92B | $14.59B | $13.11B | $10.50B | $11.13B | $9.27B | $9.13B | $7.09B | $7.57B |
| Operating income | $8.61B | $8.98B | $8.91B | $8.37B | $7.37B | $6.87B | $3.69B | $5.15B | $1.53B | $3.71B | $2.51B | $2.39B |
| Net income | $6.45B | $7.09B | $7.40B | $6.64B | $5.58B | $5.66B | $2.76B | $4.41B | $970.30M | $2.97B | $2.24B | $2.19B |
Balance Sheet
As of Dec 2025, total debt of $42.50B exceeded cash and equivalents by $35.23B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $112.48B | $78.72B | $64.01B | $49.49B | $48.81B | $46.63B | $39.29B | $43.91B | $44.98B | $38.81B |
| Current assets | $55.63B | $32.74B | $25.73B | $18.03B | $18.45B | $17.46B | $13.71B | $20.55B | $19.20B | $15.10B |
| Cash and equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B | $3.66B | $2.34B | $7.32B | $6.54B | $4.58B |
| Total liabilities | $85.94B | $64.44B | $53.14B | $38.71B | $39.65B | $40.81B | $36.59B | $33.00B | $33.31B | $24.73B |
| Short-term debt | $1.64B | $5.12B | $6.90B | $1.50B | $1.54B | $8.70M | $1.50B | $1.10B | $3.71B | $1.94B |
| Long-term debt | $40.87B | $28.53B | $18.32B | $14.74B | $15.35B | $16.59B | $13.82B | $9.20B | $9.94B | $8.37B |
| Shareholder equity | $26.54B | $14.27B | $10.77B | $10.65B | $8.98B | $5.64B | $2.61B | $9.83B | $11.59B | $14.01B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $148.07B | $142.28B | $116.58B | $112.48B | $114.94B | $100.92B | $89.39B | $78.71B | $75.61B | $71.87B | $63.94B | $64.01B |
| Total liabilities | $107.80B | $108.40B | $85.38B | $85.94B | $91.08B | $82.57B | $73.54B | $64.44B | $61.29B | $58.24B | $51.05B | $53.14B |
| Cash and equivalents | $4.88B | $8.95B | $5.28B | $7.16B | $9.79B | $3.38B | $3.09B | $3.27B | $3.37B | $3.22B | $2.46B | $2.82B |
| Shareholder equity | $40.27B | $33.88B | $31.20B | $26.54B | $23.79B | $18.27B | $15.76B | $14.19B | $14.24B | $13.56B | $12.81B | $10.77B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 53.4% of operating cash flow. Dividends and share repurchases together came to 105.8% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $16.81B | $8.82B | $4.24B | $7.59B | $7.37B | $6.50B | $4.84B | $5.52B | $5.62B | $4.85B |
| Capital expenditures | $7.84B | $5.06B | $3.45B | $1.85B | $1.31B | $1.39B | $1.03B | $1.21B | $1.08B | $1.04B |
| Free cash flow | $8.97B | $3.76B | $792.00M | $5.73B | $6.06B | $5.11B | $3.80B | $4.31B | $4.54B | $3.81B |
| Dividends paid | $5.38B | $4.68B | $4.07B | $3.54B | $3.09B | $2.69B | $2.41B | $2.31B | $2.19B | $2.16B |
| Share repurchases | $4.11B | $2.50B | $750.00M | $1.50B | $1.25B | $500.00M | $4.40B | $4.15B | $299.80M | $600.10M |
| Investing cash flow | -$10.97B | -$9.30B | -$7.15B | -$3.76B | -$2.87B | -$2.26B | -$8.08B | $1.91B | -$3.78B | -$3.14B |
| Financing cash flow | -$2.21B | $1.23B | $3.50B | -$5.41B | -$4.13B | -$3.14B | -$2.32B | -$5.90B | $142.60M | -$559.80M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $11.40B | $10.69B | $5.33B | $3.22B | $8.84B | $3.09B | $1.67B | $2.47B | $3.71B | $1.47B | $1.17B | -$312.00M |
| Capital expenditures | $3.18B | $2.93B | $2.33B | $2.55B | $2.09B | $1.70B | $1.51B | $1.50B | $1.35B | $1.22B | $986.30M | $1.07B |
| Free cash flow | $8.22B | $7.76B | $3.01B | $677.90M | $6.75B | $1.39B | $156.00M | $977.70M | $2.36B | $241.40M | $179.70M | -$1.38B |
Frequently Asked Questions About LLY
What is Eli Lilly and Company's annual revenue?
Eli Lilly and Company reported revenue of $65.18B for the fiscal year ended Dec 31, 2025.
How fast is Eli Lilly and Company's revenue growing?
Revenue was up 44.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 31.7%.
Is Eli Lilly and Company profitable?
Yes. Eli Lilly and Company reported net income of $20.64B for the fiscal year ended Dec 31, 2025, with a net margin of 31.7%.
How much free cash flow does LLY generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $16.81B minus capital expenditures of $7.84B produced free cash flow of $8.97B.
How much debt does Eli Lilly and Company have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $40.87B, short-term debt of $1.64B and cash and equivalents of $7.27B.
LLY pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts